

Special Issue

Progress in the Management and Treatment of Diffuse Large B-Cell Lymphoma: Diagnosis, Risk Stratification and Novel Target Therapeutic Approaches

Message from the Guest Editor

Since 2002, the addition of rituximab has improved the efficacy of the CHOP regimen in diffuse large B-cell lymphoma (DLBCL), with 55–60% of patients being cured, and it is still the standard of care today. However, 40–45% fail, and this has prompted many attempts to improve the efficacy of first-line treatment in DLBCL. Genetic subgroups, such as high-grade B-cell lymphomas with genetic anomalies of MYC, and/or other genes, such as BCL2, have been described, but they require a better description. Many attempts to improve the efficacy of first-line treatment in DLBCL have been studied in order to pass over the “wall” of R-CHOP, unfortunately with conflicting results. The introduction of novel targeted agents along with chemoimmunotherapy, or the introduction of novel antibodies and/or cellular immunotherapies, such as CART, promises to improve the outcomes of DLBCL. With this Special Issue, I am proposing an extended review on these open issues and novel therapeutic approaches in DLBCL, with the aim to improve our knowledge in the management and treatment of DLBCL, focusing on the most aggressive subgroups.

Guest Editor

Prof. Dr. Umberto Vitolo

Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, str Provinciale 142, Candiolo, 10126 Torino, Italy

Deadline for manuscript submissions

closed (30 September 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/71895

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)